1[1]Hosaka M,Yaxue T, Fukuda H, Tomizawa H, et al.In vitro and in vivo antibacterial activities of AM-1 155, a new 6-fluoro-8-methoxy quinolone. Antimicrobial Agents Chemotherapy, 1992;36:2108～2117.
2[2]Wakabayashi E, Mitsuhashi S. In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methyoxy quinolone. Antimicrobial Agents Chemotherapy, 1994;38:594～601.
3[3]Wise R, Brenwald NP, Andrews JM,et al. The activity of the methylpiperazinyl fluoroquinolone CG5501:A comparison with other fluoroquinolones fluoroquinolones. Antimicrobial Chemotherapy, 1997;39:447～452.
4[4]National Committee for Clinical Laboratory Standards. 1998;18.
5[5]Hosaka M,Kinoshita S, Toyama A,et al. Antibacterial Properties of AM-1155, a new 8-methoxy quinolone. Antimicrobial Chemotherapy, 1995; 36:293～301.
6[6]Tanaka M,Takahashi K, Saika T, et al. Development of fluoroquinoloneresistance and mutations involving GyrA and ParC proteins among Neisseria gonorrhoeae in Japan. Urology, 1998; 159:2215～2219.
7[7]Deguchi T, Yasuda M, Nakano M,ea al. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GryA and ParC.Chemotherapy, 1997;43:239～244.
8[8]Nakashima M,Uematsu T,Kosuge K, et al. Single and multiple-dose pharmacolinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrobial Agents Chemotherapy,1995;39:2635～2640.
1Davies B1, Maesen FP. Clinical effectiveness of levofloxacin in patients with acute purulent exacerbations of chronic bronchitis: the relationship with in-vitro activity [J]. J Antimicrob Chemother,1999, 43(Supple C): 83- 90.
2DeAbate CA, Russell M. Safety and efficacy of oral levofloxacin versus cefuroxime axetil in acute bacterial exacerbations of chronic bronchitis[J]. Respir Care, 1999, 44(2) : 206- 213.
3File TM Jr, Segreti J, Dunbar L, et al. A multi-center, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil intreatment of adults with community-acquired penumonia[J]. Antimicrob Agents Chemother, 1997, 41(9) : 1965 - 1972.
